USA, Rio Rancho-based life sciences company, Nature’s Toolbox, Inc. (NTx), has raised $47.5 million in Series B financing, led by RA Capital Management, with Dr. Peter Kolchinsky joining NTx’s Board of Directors. Led by CEO Jamie Coffin, Ph.D., NTx plans to use the funds to advance its biomanufacturing platforms, NTxscribe® and NTxpress®, aimed at eco-friendly and sustainable manufacturing of mRNA vaccines and protein therapeutics. NTxscribe, a continuous flow manufacturing system, is being utilized in BioPharma R&D for mRNA therapeutic development and is part of the first Vaccines-on-Demand contract awarded by BARDA DRIVe for pandemic preparedness. NTxpress is a recombinant cell-free expression system minimizing unwanted cellular metabolism in protein production.